Midsize Japanese Pharmas Seen As Major Drivers Of Merger Mania
This article was originally published in PharmAsia News
Midsize Japanese pharmaceuticals are seen as reaping most of the benefits of a global merger fever in the industry as foreign firms look to Japan for business opportunities. Japan does not expect to see a slowdown in the mergers-and-acquisition activity this year, following up on major merger activity of last year. An investment executive says midsize firms facing loss of patent protection for some of their drugs, plus government efforts to drive down the cost of drugs in Japan, will begin restructuring, including taking on M&As, to stay afloat and compete. (Click here for more - a subscription may be required
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.